Ronald Sugar - Amgen Insider

Amgen Inc -- USA Stock  

USD 183.55  0.05  0.0272%

Independent Director

Dr. Ronald D. Sugar, Ph.D., is an Independent Director of Amgen Inc. Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporationrationration, a global aerospace and defense company, having held these posts from 2003 through 2009. Dr. Sugar was a director of Chevron Corporationrationration, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee and of Air Lease Corporationrationration, an aircraft leasing company, since 2010, chairing the Compensation Committee and serving on the Governance Committee. Since 2010, he was a senior advisor to Ares Management LLC, a privatelyheld asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore
Age: 68  Director Since 2010      
805-447-1000  http://www.amgen.com
Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, director of the Los Angeles Philharmonic Association and national trustee of the Boys and Girls Clubs of America.

Ronald Sugar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.32 % which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 7.18 % meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Elaine UllianVertex Pharmaceuticals Incorpor
2011
Deborah NeffBio Rad Laboratories Inc
2011
William YoungVertex Pharmaceuticals Incorpor
2014
Ronald TaylorAllergan plc
2013
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Jill SmithEndo International plc
2012
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Fred WeissAllergan plc
2013
James FarrellAbbott Laboratories
2006
Peter McDonnellAllergan plc
2015
Ron TaylorAllergan plc
2013
Sally BlountAbbott Laboratories
2011
Roxanne AustinAbbott Laboratories
2000
Sharad MansukaniEndo International plc
2017
Patrick OSullivanAllergan plc
2013
Alan GarberVertex Pharmaceuticals Incorpor
2017
Robert AlpernAbbott Laboratories
2008
Alice SchwartzBio Rad Laboratories Inc
1967
William OsbornAbbott Laboratories
2013
Arthur HigginsEndo International plc
2013
Christopher BodineAllergan plc
2013

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators